Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2026-01-08 @ 4:24 PM
Study NCT ID:
NCT02185560
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-23
First Post:
2014-07-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-06-27
Start Date Type:
ACTUAL
Primary Completion Date:
2020-02-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2014-07-04
First Submit QC Date:
None
Study First Post Date:
2014-07-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-22
Last Update Post Date:
2025-07-23
Last Update Post Date Type:
ACTUAL